However, Fisher et al. demonstrated that liver CYP2C19 mRNA downregulation in NASH (p = 0.193) corresponded to a significant decrease in liver CYP2C19 enzyme abundance (p = 0.01)25, indicating CYP2C19 mRNA is a good surrogate measure for CYP2C19 enzyme abundance. Here, CYP2C19 is linked to metabolic dysfunction-associated steatohepatitis.